ATAI Company Profile and Key Details

ATAI has shown mixed momentum, gaining 2.39% over the past week and -40.31% over the past quarter, though year-to-date performance is down -5.87%. Short-term trend indicators are mixed aligned (SMA20 -2.95%, SMA50 -4.66%, SMA200 -4.4%). The stock’s 14-day RSI is 46.18 (neutral), while the ATR of 0.31 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -44.74% below its high and over 224.35% above its low. Average 10-day trading volume of 5.11 million shares is below the 3-month average of 5.86 million, indicating normal recent market interest.

Atai Beckley Inc. has 363.21 million shares outstanding. The public float is 302.85 million shares, elevated short interest at 5.65% of float. This equals 17.37 million shares. The short ratio is 3.27 days. Institutional investors hold 30.17% of the float. Insiders own 6.67%. Apeiron Investment Group Ltd. holds 51.05 million shares, ATAI Life Sciences N.V. has 12.00 million shares and Auerbach Michael has 5.56 million shares.

Atai Beckley Inc. generated EPS of $nan over the past year. Five-year average earnings growth is 18.62%. Wall Street analysts project EPS growth of 19.84% annually over the next five years. The latest quarter delivered EPS of -$0.08. The next quarter is forecast at -$0.10. Next year's EPS is expected at -$131.78. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 14 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $25.00 to $11.00. The high target offers 455.56% upside. The low target suggests 144.44% downside. The mean target is $15.13. This offers 236.22% upside. Atai Beckley Inc. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by -38.46%. The prior quarter beat by -58.33%. Over the last six quarters, Apple has recorded several small beats. These include 71.43% in March 17, 2025.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Atai Beckley Inc. (NASDAQ:ATAI) closed at $4.50 USD, losing -$0.03 (-0.66%) from the previous close of $4.53. The stock is currently mid-range between its 52-week high and low $2.00 and $6.75. With a market capitalization of about $1.66 billion, Atai Beckley Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.60). Key stats such as the average daily volume over the past year has been around 5.78 million shares, in line with its 52-week average. Headquartered in New York, NY, Atai Beckley Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Christian Angermayer, the company employs approximately 99 people and listed since June 18, 2021. AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.

Atai Beckley Inc. trades at a P/E ratio of -1.55, slightly below the S&P 500 average, with a price-to-sales ratio of 479.74 and a price-to-book ratio of 5.18 trading at moderately above to book value. The P/FCF stands at -14.28, also below market averages.

Our AI price prediction model suggests that Atai Beckley Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.22%, with price expected at $4.60 by June 17, 2026, within a range of $4.24 to $4.98 3-Month Outlook: Projected fall of -26.44%, reaching $3.31 by September 01, 2026, with a range of $3.00 to $3.56. 1-Year Outlook: Projected gain of 281.11%, with price at $17.15 by June 03, 2027, within a range of $9.53 to $25.05.

Atai Beckley Inc. (NASDAQ:ATAI) shares are flat -5.87% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Atai Beckley Inc. trading at a premium to the broader market with a P/E of -1.55. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $16.21, suggesting 260.22% upside. Our AI forecast model points to short-term strength (2.22% over two weeks), a medium-term fall (-26.44% over three months), and a longer-term gain (281.11% over one year), with expected trading ranges indicating moderate volatility.